NCT04260854View on ClinicalTrials.gov

Bupivacaine Hydrochloride for Pain Control in Cutaneous Surgery

PHASE1Enrolling by invitationINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

January 24, 2024

Primary Completion Date

June 30, 2025

Study Completion Date

June 30, 2025

Conditions
Pain, Postoperative
Interventions
DRUG

Bupivacaine Hydrochloride

Bupivacaine hydrochloride (Hospira, Inc) is an FDA approved, local, injectable indicated for the production of local or regional anesthesia or analgesia for surgery.

DRUG

Saline

Normal saline injections.

Trial Locations (1)

60611

Northwestern University Department of Dermatology, Chicago

All Listed Sponsors
lead

Northwestern University

OTHER